Breast Neoplasm Female

Oncology
3
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 2 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Bristol Myers Squibb
1 program
1
NivolumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT03650894Active Not Recruiting30Est. Dec 2026
Providence Therapeutics
1 program
1
NivolumabPhase 2Monoclonal Antibody
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]Phase 11 trial
Active Trials
NCT03691311Unknown60Est. Feb 2023
Genomics
GenomicsUK - Oxford
1 program
ARNA BreastN/A1 trial
Active Trials
NCT04927130Unknown150Est. Dec 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bristol Myers SquibbNivolumab
AmgenDenosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
GenomicsARNA Breast

Clinical Trials (3)

Total enrollment: 240 patients across 3 trials

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Start: Apr 2019Est. completion: Dec 202630 patients
Phase 2Active Not Recruiting
NCT03691311AmgenDenosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]

Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer

Start: Jul 2018Est. completion: Feb 202360 patients
Phase 1Unknown

Retrospective Comparative in Vitro Case-controlled Study of the Liquid Biopsy Test System in Women With Breast Cancer

Start: Jun 2021Est. completion: Dec 2021150 patients
N/AUnknown

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space